NEW DELHI: Zydus Lifesciences Ltd introduced on Wednesday that Mamitra, a Trastuzumab biosimilar used to deal with varied kinds of cancer, has been granted marketing approval by the Mexican regulatory authority.
Mamitra is used within the treatment of breast cancer and superior gastric cancer. The firm famous that breast cancer has surpassed prostate and colorectal cancers to develop into essentially the most recognized cancer in Mexico.
“The approval of Mamitra in Mexico allows us to expand the reach of our biosimilar portfolio to newer markets and enable access to affordable life-saving therapies, particularly in oncology,” stated Dr Sharvil Patel, managing director of Zydus.
The approval, given by COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), permits the drug to be marketed in several strengths of 150 mg and 440 mg, as per the corporate’s regulatory submitting.
The Trastuzumab biosimilar was developed in-house by the analysis workforce on the Zydus Research Centre (ZRC) and launched in India in 2016 below the model title Vivitra. Since its launch, an estimated 1 lakh sufferers have been handled with the remedy, in response to the corporate.
Mamitra is used within the treatment of breast cancer and superior gastric cancer. The firm famous that breast cancer has surpassed prostate and colorectal cancers to develop into essentially the most recognized cancer in Mexico.
“The approval of Mamitra in Mexico allows us to expand the reach of our biosimilar portfolio to newer markets and enable access to affordable life-saving therapies, particularly in oncology,” stated Dr Sharvil Patel, managing director of Zydus.
The approval, given by COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), permits the drug to be marketed in several strengths of 150 mg and 440 mg, as per the corporate’s regulatory submitting.
The Trastuzumab biosimilar was developed in-house by the analysis workforce on the Zydus Research Centre (ZRC) and launched in India in 2016 below the model title Vivitra. Since its launch, an estimated 1 lakh sufferers have been handled with the remedy, in response to the corporate.
